EMAIL THIS PAGE TO A FRIEND

International journal of environmental research and public health

Constitutive, but not challenge-induced, interleukin-10 production is robust in acute pre-pubescent protein and energy deficits: new support for the tolerance hypothesis of malnutrition-associated immune depression based on cytokine production in vivo.


PMID 21318019

Abstract

The tolerance model of acute (i.e., wasting) pre-pubescent protein and energy deficits proposes that the immune depression characteristic of these pathologies reflects an intact anti-inflammatory form of immune competence that reduces the risk of autoimmune reactions to catabolically released self antigens. A cornerstone of this proposition is the finding that constitutive (first-tier) interleukin(IL)-10 production is sustained even into the advanced stages of acute malnutrition. The IL-10 response to inflammatory challenge constitutes a second tier of anti-inflammatory regulation and was the focus of this investigation. Weanling mice consumed a complete diet ad libitum, a low-protein diet ad libitum (mimicking incipient kwashiorkor), or the complete diet in restricted daily quantities (mimicking marasmus), and their second-tier IL-10 production was determined both in vitro and in vivo using lipopolysaccharide (LPS) and anti-CD3 as stimulants of innate and adaptive defences, respectively. Both early (3 days) and advanced (14 days) stages of wasting pathology were examined and three main outcomes emerged. First, classic in vitro systems are unreliable for discerning cytokine production in vivo. Secondly, in diverse forms of acute malnutrition declining challenge-induced IL-10 production may provide an early sign that anti-inflammatory control over immune competence is failing. Thirdly, and most fundamentally, the investigation provides new support for the tolerance model of malnutrition-associated inflammatory immune depression.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

12107C
Fetal Bovine Serum, USA origin, γ-irradiated by SER-TAIN® process, sterile-filtered, suitable for cell culture
12303C
Fetal Bovine Serum, USDA approved countries, sterile-filtered, cell culture tested
12007C
Fetal Bovine Serum, Australia origin, γ-irradiated, sterile-filtered, suitable for cell culture
12203C
Fetal Bovine Serum, New Zealand origin, sterile-filtered, suitable for cell culture
12006C
Fetal Bovine Serum, Australia origin, USDA approved, Heat Inactivated, suitable for cell culture
12207C
Fetal Bovine Serum, New Zealand origin, cell culture tested
F9423
Fetal Bovine Serum, Australia origin, suitable for, USDA approved, sterile-filtered, suitable for cell culture, suitable for hybridoma
F3297
Fetal Bovine Serum, Australia origin, γ-irradiated, suitable for cell culture, suitable for hybridoma
12105C
Fetal Bovine Serum, Dialyzed by ultrafiltration against 0.15M NaCl, USA origin, sterile-filtered, cell culture tested
12106C
Fetal Bovine Serum, USA origin, Heat Inactivated, sterile-filtered, suitable for cell culture
L4005 Lipopolysaccharides from Escherichia coli O55:B5, purified by trichloroacetic acid extraction
L2637 Lipopolysaccharides from Escherichia coli O55:B5, purified by gel-filtration chromatography
L4524
Lipopolysaccharides from Escherichia coli O55:B5, purified by ion-exchange chromatography, TLR ligand tested
F8666 Lipopolysaccharides from Escherichia coli O55:B5, FITC conjugate
L9023 Lipopolysaccharides from Escherichia coli O55:B5, Detoxified
L5418 Lipopolysaccharides from Escherichia coli O55:B5, Ready Made solution, 1 mg/mL, 0.2 μm filtered